Monoclonal ant-idiotypic antibodies reactive with a highly conserved determinant on A/J serum anti-para-azophenylarsonate antibodies by unknown
MONOCLONAL  ANTI-IDIOTYPIC  ANTIBODIES  REACTIVE 
WITH  A  HIGHLY  CONSERVED  DETERMINANT  ON  A/J 
SERUM  ANTI-p-AZOPHENYLARSONATE  ANTIBODIES* 
By MITCHELL J.  NELLES, LORRAINE A. GILL-PAZARIS,§ 
AND ALFRED NISONOFF 
From The Rosenstiel Basic Medical Sciences Research Center, Department of Biology, Brandeis University, 
Waltham,  Massachusetts 02254 
The humoral response to the azobenzenearsonate (Ar) 1 hapten  in  the A/J strain 
includes at least three definable populations of antibodies. One population comprises 
the major cross-reactive idiotype (CRI) found in all  immunized mice; in individual 
mice the CRI generally constitutes 20-70% of the anti-Ar population  (1).  A  second 
population, which has been designated the minor CRI, ordinarily constitutes 5-10% 
of the anti-Ar antibodies (2-4). These molecules are clearly distinguishable from the 
major  idiotype and  appear  to  be  quite  heterogeneous.  Conventional anti-idiotypic 
antiserum prepared in a  rabbit  includes molecules reactive with both the major and 
minor CRI populations  (3,  4).  The  minor CRI in  the  A/J strain  corresponds to  a 
major CRI in BALB/c mice (5, 6); thus, anti-idiotype directed to the minor CRI of 
A/J  anti-Ar antibodies  reacts with  5-10% of an  A/J anti-Ar population,  but  with 
-40%  of  BALB/c  anti-Ar  antibodies.  Approximately  the  same  population  of 
BALB/c antibodies  is  recognized  by anti-CRI  prepared  against  BALB/c anti-Ar. 
Individual A/J mice also produce anti-Ar antibodies with idiotypes that are unique 
to  individual  mice  and  may  be  present  in  undetectable  concentrations  in  other 
immunized mice of the same strain  (7). 
Serological and amino acid sequence analyses have been carried out on hybridoma 
products expressing the  major CRI  (8-13).  These  have shown  that  the  major CRI 
constitutes a  large family of related but nonidentical molecules. Variations in amino 
acid sequence within the family occur both in framework and hypervariable regions. 
However, the degree of homology, when sequences of heavy or light chains from two 
members of the family are compared, exceed 90% (8-11)  (J. D. Capra; M. Margolies, 
personal communications). 
The presence of a  conserved idiotypic determinant  in  molecules constituting the 
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major  CRI  was  indicated  by  serological  studies  in  which  heterologous  anti-CRI 
prepared against one CRI + hybridoma product  (HP)  was allowed to interact with a 
different, labeled HP  that also carried the CRI  (13).  When various unlabeled CRI + 
HP  were  tested  as  inhibitors  of  binding,  it  was  found  that  12  of  14  HP  were 
quantitatively equivalent in their inhibitory capacities. This suggests the presence of 
at least one conserved idiotypic determinant in molecules carrying the major CRI but 
does not provide information concerning the nature of the conserved determinant(s). 
We have now taken a  direct approach to the question of the presence of conserved 
idiotypic determinants in A/J  serum Anti-Ar antibodies and in CRI + HP.  This was 
done by preparing monoclonal  anti-idiotypic antibodies against A/J  serum  anti-Ar 
and studying their interactions with individual CRI + hybridoma products and with 
serum  anti-Ar.  The  data  indicate  that  a  large  proportion  of A/J  serum  anti-Ar 
antibodies and 8 of 10 CRI + HP share at least one idiotypic determinant definable by 
monoelonal  anti-CRI  antibodies.  The  shared  determinant  is  associated  with  the 
hapten-binding site of the CRI  + HP. In addition, functional studies were carried out 
to ascertain whether monoclonal anti-idiotypic antibodies are capable of suppressing 
CRI formation when inoculated into adult A/J mice. 
Materials  and  Methods 
Preparation of Hybridomas Secreting Anti-CRI Antibodies.  Adult  BALB/c  mice  (The Jackson 
Laboratory,  Bar  Harbor,  Maine)  were  immunized  with  specifically purified  A/J  anti-Ar 
antibodies that had been polymerized with glutaraldehyde by the method of Daugharty et al. 
(14).  Mice were  immunized a  total of three  times intraperitoneally with  250  pg of anti-Ar 
antibody emulsified in complete Freund's adjuvant. 3 d before killing, animals were immunized 
via both  the intraperitoneal and  intravenous routes, with the latter immunization given in 
saline.  Spleen  cells  depleted  of erythrocytes  from  a  single  mouse  were  used  to  prepare 
hybridomas by the method of KShler and Milstein (15), as modified by Gefter et al. (16). The 
BALB/c tumor line used,  Sp2/O-Agl4, was developed by Shulman  et  al.  (17);  it does not 
secrete heavy or light chains before or after fusion.  1 ×  108 splenic leukocytes and  2  ×  107 
tumor cells were fused with 30%  polyethylene glycol (PEG-1000, J.  T.  Baker Chemical Co., 
Phillipsburg, N. J.). Immediately after fusion, cells were transferred to 96-well tissue culture 
plates (Costar Co., Cambridge, Mass.) at a concentration of 3.3  X  104 tumor cell equivalents 
per well, in Dulbecco's modified Eagle's medium supplemented with  10% horse serum, and 
antibiotics (Gibeo Laboratories, Grand Island Biological Co., Grand Island, N. Y.). 24 h later, 
hybrid cells were selected in medium that contained hypoxanthine, thymidine, and aminop- 
terin, as described by Littlefield (18). Of the 504 wells originally plated, 103 showed macroscopic 
growth 21/2 wk after fusion. Culture supernatants were assayed for anti-CRI antibody by solid- 
phase radioimmune assay (19)  using polyvinyl chloride microtiter trays containing adsorbed 
purified A/J  anti-Ar antibodies. All assays were carried out  in the presence of normal A/J 
serum to avoid detection of antibodies with specificity for A/J allotypic determinants. Bound 
anti-CRI antibodies were detected by measuring the subsequent uptake of 12~I-labeled purified 
A/J serum anti-Ar antibody to the tray. Individual cell culture supernatants obtained from 
growth-positive wells were assayed in this manner and three were found to contain anti-CRI 
antibodies. Each hybrid was derived from a separate culture well, and, because cells were plated 
out immediately after fusion, each represents the product of an independent fusion event. The 
cells  from  anti-CRI-positive wells were  transferred  into  larger  (24-well)  Costar  plates  and 
subsequently cloned in soft agarose, as described by K6hler and  Milstein (15).  Clones were 
visible in  14-21  d. Individual clones were transferred with a Pasteur pipet to microtiter plates 
and grown into mass culture. Large amounts of monoclonal antibody were produced in mice 
that had been primed with pristane (Aldrich Chemical Co., Milwaukee, Wis.) (20). A globulin 
fraction of each  monoclonal  anti-CRI  was  first  prepared by precipitation with  ammonium 
sulfate (40% saturation). The dissolved globulin was fraetionated on DEAE-cellulose by stepwise 
elution with increasing concentrations of phosphate buffer, pH 8. Each of the three monoclonal 1754  MONOCLONAL ANTI-IDIOTYPIC ANTIBODIES 
anti-CRI antibodies (7B7.10, 2F6.4, IF2.1) migrated as a single sharp band upon electrophoresis 
in agarose; the three proteins differed in electrophoretic mobility. Ouchterlony analysis showed 
that each protein is IgGiK. 
Reagents.  All of the anti-Ar hybridoma proteins used in these studies, with the exception of 
123E6 and 124E1, were the generous gift of Dr. Edmundo Lamoyi, Brandeis University, and 
were  specifically purified as  previously described  (13). Anti-Ar HP  123E6  and  124E1 were 
kindly supplied by Dr. J. D. Capra, University of Texas Health Science Center, Dallas, Texas 
(13). Serum designated HIS (hyperimmune, suppressed)  was obtained from A/J mice that had 
been idiotypically suppressed by inoculation of heterologous anti-CRI serum  (21) and then 
hyperimmunized with keyhole limpet hemocyanin-Ar (KLH-Ar). Hyperimmunized animals 
that are immunologically  suppressed for the A/J CRI (HIS) serum contain a high concentration 
of anti-Ar antibodies that are not inhibitory in the standard'radioimmune  assay for CRI. 
Proteins were conjugated to Sepharose 4B (Pharmacia Fine Chemicals, Piscataway, N. J.) by 
using cyanogen bromide (22). Approximately 200 gg of anti-CRI antibody was conjugated per 
cm  3 of beads. Rabbit serum containing  anti-CRI antibody specific for the major CRI of the Ar- 
binding hybridoma protein R16.7  [anti-CRI (R16.7)]  was  the generous gift  of Dr.  Thomas 
Kresina, Brandeis University. Sepharose columns containing bound anti-CRI antibodies were 
assayed  for their binding capacities by determining the weight of 125I-labeled purified A/J 
serum anti-Ar antibody bound by a given volume of beads at saturation. Proteins were labeled 
with 125I by the chloramine-T method of Hunter (23). 
The  haptens, p-arsanilic acid  (Eastman  Kodak  Co.,  Rochester,  N.  Y.),  o-arsanilic acid 
(Aldrich Chemical Co.,  Milwaukee, Wis.),  and p-aminobenzoic acid  (Fisher Scientific Co., 
Fairlawn, N. J.) were recrystallized twice from hot water. The 2-ring hapten m-azobenzene-p'- 
arsonate-3(p-hydroxphenyl)-propionic  acid (Ar-HPP) was the gift  of Dr.  Edmundo Lamoyi, 
and m-arsanilic acid was the gift of Dr. Oliver Roholt, Roswell Park Institute, Buffalo, N. Y. 
Assays for Anti-Ar Antibodies and CR1.  Anti-Ar antibodies in serum were quantified by the 
polyvinyl chloride tray method of Klinman et al.  (19), using BSA-Ar-coated trays with 12Sl- 
labeled specifically purified rabbit anti-mouse Fab as the developing reagent. The content of 
CRI in serum samples was determined by radioimmune assay, as previously described (1,  12). 
The assay utilized  10 ng of 125I-labeled purified A/J serum anti-Ar antibody together with 
heterologous anti-CRI in a quantity sufficient to bind slightly less than a maximum amount of 
ligand. Complexes were precipitated with excess goat anti-rabbit Fc antiserum. Unlabeled sera 
or antibodies were tested as inhibitors of binding. 
Characterization ofAnti-CRl Hybridoma Proteins.  Solid-phase radioimmune assays using poly- 
vinyl chloride microtiter trays were used to study anti-CRI hybridoma proteins (anti-CRI HP) 
in a number of different assays. In one assay system, wells were coated with various anti-CRI 
HP for determination of their fine specificity.  Inhibitors were added, followed by  10 ng 125I- 
labeled purified serum anti-Ar antibody or 125I-labeled CRI  + HP R16.7. Data are expressed  as 
the weight of unlabeled inhibitory protein causing a 50% reduction in binding of radiolabeled 
anti-Ar antibody or R16.7 to the immobilized anti-CRI PIP. To determine whether anti-CRI 
HP interact with CRI  ÷ antibody molecules through a determinant close to the antigen-binding 
site,  wells were coated with HP R16.7; hapten diluted in saline-borate buffer containing 2% 
horse  serum was  added,  followed  by  12~I-labeled anti-CRI HP.  Data  are  expressed  as  the 
concentration of hapten required to cause a  50% reduction in the binding to  R16.7  of the 
various radiolabeled anti-CRI HP. To compare the avidities of the various anti-CRI HP, wells 
were coated with purified serum anti-Ar antibody or HP R16.7 and incubated with unlabeled 
anti-CRI HP.  10  ng of a  particular 125I-labeled anti-CRI HP  was  then  added.  Data  are 
expressed  as the weight of unlabeled anti-CRI HP required to cause a  50% reduction in the 
binding of individual radiolabeled anti-CRI HP to immobilized CRI  ÷ proteins. 
Results 
Table I  shows  the  maximum percentages of labeled purified A/J  serum  anti-Ar 
antibodies or of the CRI  + HP R16.7 that were bound by several anti-CRI prepara- 
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TABLE I 
Maximum Percentages  of Labeled, Purified A/J Anti-At Antibody or of Labeled CRI  + HP 1716.  7 Bound 
by Various Anti-CR1 Preparations 
125I-labeled protein 
Adsorbent (anti-CRI conjugated to Sepharose) 
RaCRI  7B7.10'  2F6.4"  IF2.1*  Mixture~:  (R16.7)§  RaCRIII 
Percent labeled  protein bound 
Purified anti-Ar¶  34  41  28  41  66  80 
R16.7"*  84  77  74  --  81  -- 
nMIgG  2  2  2  --  6  7 
*  Anti-CRI HP. 
:[:  Mixture of equal weights of 7B7.10, 2F6.4, and 1F2.1. 
§  Rabbit anti-CRl serum specific for HP R16.7 (CRI+). 
l[  Rabbit anti-CRI serum specific for A/J serum anti-At antibody. 
¶  From pooled sera of immunized A/J mice. 
** RI6.7 is a CRI  + HP. 
that  the column  capacity was  in  large  excess  with  respect  to the  weight  of labeled 
ligand used. 
There is considerable variation in the percentage of labeled purified serum anti-Ar 
bound by the five anti-CRI preparations.  Rabbit  anti-CRI specific for R16.7 bound 
66% of this ligand, whereas conventional rabbit anti-CRI bound 80%. The difference 
is attributable to the presence of a  "minor" cross-reactive idiotypic population within 
A/J sera (1-4). The conventional anti-CRI reacts with the minor population, whereas 
anti-CRI directed against  R 16.7, a  representative  of the major idiotypic population, 
does  not.  The  minor idiotype  is  serologically distinct  from the  major cross-reactive 
idiotype. Of the three anti-CRI HP 2F6.4 bound the highest percentage  (41%) of the 
purified A/J serum anti-Ar antibodies.  The fact that  anti-CRI HP bound a  smaller 
percentage  of the  CRI  +  antibodies  than  did  rabbit  anti-CRI  directed  to  R16.7  is 
consistent  with  microheterogeneity  in  the  CRI  +  population  (3,  12).  All  three  anti- 
CRI  HP  bound  labeled  R16.7,  which  is  a  CRI  ÷  HP  (74-84%  bound);  that  100% 
binding was not attained is probably attributable to partial denaturation of the R16.7 
HP during iodination. 
The most significant  aspect  of these results  is  that  the monoclonal  HP  2F6.4 was 
able  to  bind  41%  of the  purified  anti-Ar  serum  antibody  or  about  60%  of the 
antibodies  that  are  recognized  by  rabbit  anti-CRI  directed  to  R16.7.  This  result 
indicates  that  at  least  60%  of the  CRI  +  population  contains  a  highly  conserved 
idiotypic  determinant,  recognizable  by  a  monoclonal  antibody.  The  fact  that  a 
mixture of the three anti-CRI HP bound the same percentage of purified anti-Ar that 
was  bound  by  HP  2F6.4  (Table  I)  indicates  that  the  three  monoclonal  anti-CRI 
antibodies react with overlapping subpopulations of the anti-Ar antibodies. 
To  determine  whether  anti-CRI  HP  2F6.4  bound  a  subpopulation  of antibodies 
that  were  bound  by rabbit  anti-CRI(R16.7),  labeled  serum  anti-Ar  that  remained 
unbound by an anti-CRI(R 16.7)  column was applied to a Sepharose column contain- 
ing immobilized anti-CRI HP, 2F6.4.  Only  1% of the label was bound by the second 
column, indicating that  2F6.4 binds a  subfraction  of the anti-Ar antibodies  that  are 
bound by anti-CRI(R16.7). 
Inhibition  of the Interaction  of Anti-CRI HP with 125I-labeled Anti-Ar Antibody or with 125I- 1756  MONOCLONAL  ANTI-IDIOTYPIC ANTIBODIES 
labeled CRI ÷ HP R16. 7.  To study the fine specificity of the anti-CRI HP, competition 
experiments were  carried  out in which  various unlabeled anti-At preparations  were 
allowed to compete with labeled purified anti-Ar antibodies for binding to anti-CRI. 
The results are shown in Tables II and III. In Table II the labeled ligand is purified 
A/J  serum anti-Ar antibody; in Table III the labeled ligand is the CRI ÷ HP, R16.7. 
As controls  for  the  experiments  of Table  II, normal  mouse IgG  (nMIgG)  and 
serum containing anti-Ar antibodies from HIS mice were tested as inhibitors. These 
preparations failed to inhibit significantly the binding of labeled anti-Ar to any of the 
anti-CRI  preparations  tested.  Similarly, the  CRI-  anti-Ar HP  R18.1 1,  R19.9,  and 
R21. I0 were noninhibitory. 
Among  the  CRI +  HP,  considerable  variation  was  observed  in  their  capacity  to 
displace  labeled  purified  anti-Ar  antibodies  from  rabbit  anti-CRI.  The  weights 
required  for  50%  inhibition of binding varied  from  15  to  2,000  ng. The  pattern  of 
inhibition seen  for  these  particular  HP  is  very similar to  that  observed  in previous 
experiments (13)  in which a  double antibody precipitation assay was used. 
In contrast,  8  of  10  of the  CRI +  HP  were  quite  similar in  their  effectiveness  as 
TABLE II 
Inhibition  of Binding of Labeled,  Purified Anti-At Antibody  to Immobilized Anti-CRl Preparations by 
Various Unlabeled Anti-Ar Preparations 
Presence  Unlabeled inhibitor  of CRI 
Anti-CRI 
Ra'CRI  7B7.10  2F6.4  1F2.1 
ng anti-At or nMIgG required  for 50% inhibition* 
nMIgG  -  >5,000  (17)  >5,000  (10)  >5,000  (0)  >5,000  (6) 
HIS serum:[:  -  >5,000  (48)  5,000  (50)  >5,000  (16)  >5,000  (49) 
A]J anti-Ar serum  +  25(100)  47(100)  67(100)  25(100) 
Purified serum  +  28  (99)  57(100)  82  (97)  25(100) 
A/J anti-Ar 
HP R16.7  +  15  (93)  23(100)  22(100)  21(100) 
HP R20.4  +  22  (81)  72  (97)  61  (96)  75  (98) 
HP R9.3  +  367  (62)  21  (97)  25  (93)  60  (97) 
HP R10.8  +  445  (54)  39  (96)  76  (93)  64(t00) 
HP R17.5  +  500  (61)  25  (95)  58  (93)  36  (98) 
HP R23.2  +  500  (56)  100  (95)  64  (93)  100(100) 
HP R24.6  +  1,000  (55)  22  (93)  78  (92)  78  (98) 
HP R22.4  +  2,000  (56)  100  (95)  56  (93)  68  (99) 
HP 123E6  +  ND§  >5,000  (27)  85  (91)  >5,000  (41) 
HP /24E1  +  ND~  >5,000  (31)  >5,000  (7)  >5,000  (35) 
HPRIS.11[I  -  >2,000  (13)**  >5,000  (34)  >5,000  (1)  >2,000  (9)** 
HP R19.911  -  >5,000  (26)  >5,000  (22)  >5,000  (1)  >5,000  (10) 
Hp 21.10  u  -  >5,000  (21)  >5,000  (15)  >5,000  (7)  >5,000  (15) 
Wells of polyvinyl chloride microtiter trays were coated  with anti-CRI HP or purified rabbit anti-CRI 
antibody. Various amounts of unlabeled inhibitor proteins  (anti-Ar) were added, followed by 10 ng ~2Sl- 
labeled, purified A/J serum anti-Ar antibodies. 
* Values in parentheses  show the percent inhibition by 5,000 ng or where  indicated (**), by 2,000 ng 
unlabeled inhibitor. 
~: Hyperimmune suppressed mice were immunologically  suppressed by pre-inoeulation of rabbit anti-CRI 
serum followed by hyperimmunization  with KLH-Ar. The serum contains a high titer of anti-Ar antibody 
but lacks the CRI. 
§ Not done. 
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TABLE  III 
Inhibition of Binding of Labeled, R16. 7 HP(CRI  +) to Immobilized Anti-CRI Preparations by Various 
Unlabeled Anti-At Preparations 
Presence  Unlabeled inhibitor  of CRI 
Anti-CRI 
RaCRI  7B7.10  2F6.4  1F2.1 
ng anti-Ar or NMIgG required  for 50% inhibition* 
nMIgG  -  >5,000  (29)  >5,000  (0)  >5,000  (0)  >5,000  (21) 
HIS serum:~  -  2,000  (65)  >5,000  (33)  >5,000  (13)  >5,000  (27) 
A/J anti-Ar serum  +  40(100)  53(100)  53(100)  52(100) 
Purified serum  +  34 (100)  57 (100)  52 (100)  88 (100) 
A/J Anti-Ar 
HP R16.7  +  17(100)  9(100)  14(100)  20(100) 
HP R20.4  +  27  (86)  51  (96)  35(100)  44(100) 
HP R9.3  +  285  (63)  5  (97)  12  (99)  24(100) 
HP RI0.8  +  500  (59)  8  (95)  24  (99)  24(100) 
Hp R17.5  +  500  (62)  9  (95)  21  (98)  21  (99) 
HPR23.2  +  500  (60)  22  (96)  38  (99)  61(100) 
HP R24.6  +  1,000  (54)  23  (93)  32(100)  24  (99) 
HP R22.4  +  2,000  (55)  18  (91)  24  (99)  66  (99) 
ttP 123E6  +  ND§  >5,000  (13)  78  (99)  >5,000  (33) 
Hp 124E1  +  ND§  >5,000  (12)  >5,000  (0)  >5,000  (42) 
HP R I8.11:]:  -  >2,000  (28)**  >5,000  (18)  >5,000  (8)  >5,000  (38) 
HP R19.9:~  -  >5,000  (33)  >5,000  (18)  >5,000  (7)  >5,000  (47) 
HP R21.10:]:  -  >5,000  (20)  >5,000  (21)  >5,000  (14)  >5,000  (38) 
Wells of polyvinyl chloride microtiter trays were coated with anti-CRI HP or purified rabbit anti-CRI 
antibody. Various amounts of unlabeled inhibitor proteins (anti-Ar)  were  added,  followed by  10 ng 
labeled R16.7 HP. 
* Values in parentheses  show the percent inhibition by 5,000 ng, or, where  indicated (**) by 2,000 ng 
unlabeled inhibitor. 
:~ As in Table II. 
§ Not done. 
inhibitors when any of the three anti-CRI HP was used as the immobilized prepara- 
tion. Although some variation in inhibitory capacity is noted, the degree of variation 
is  small  as  compared  to  that  observed  with  rabbit  anti-CRI  as  the  immobilized 
antibody. These results support the conclusion that each of the monoclonal anti-CRI 
antibodies recognizes a  determinant that is shared by 8 of the 10 CRI + HP tested; the 
results are thus consistent with the presence of a  highly conserved determinant found 
in  these  eight  CRI +  HP.  Serum  anti-Ar  antibodies  were  roughly  equivalent  in 
inhibitory capacity to the monoclonal CRI + HP,  indicating that  the same or a  very 
similar determinant is present on a  large proportion of the serum antibodies. 
The protocol for the experiments of Table III is identical to that of Table II, with 
the exception  that  the  CRI +  HP  R16.7  rather  than  serum  anti-Ar was  used  as  the 
labeled ligand. The results are very similar to those of Table II. Unlabeled CRI + HP 
vary markedly, and, with the same order of effectiveness as in Table II, as inhibitors 
of binding to rabbit anti-CRI, but 8  of 10 are strong inhibitors of binding of labeled 
HP  R16.7 to each of the three monoclonal anti-CRI antibodies. 
Effect of  Hapten on the Interaction between Anti-CRI HP and the CRI  + HP R16. 7.  Further 
evidence  concerning the  fine  specificity  of  the  monoclonal  anti-CRI  antibodies  is 
presented  in Table IV, which shows the effects of haptens on the binding of labeled 1758  MONOCLONAL ANTI-IDIOTYPIC ANTIBODIES 
monoclonal anti-CRI, or labeled purified rabbit anti-CRI, to immobilized CRI + HP 
R16.7.  Each derivative of arsanilate inhibited binding of each monoclonal anti-CRI 
antibody; the strongest inhibitor is the 2-ring hapten, Ar-HPP. Among the arsanilate 
compounds, the order of inhibitory capacity is (p >  m >  0). These results are consistent 
with relative binding affinities of haptens observed with rabbit anti-p-azobenzenear- 
sonate  antibodies  (24).  The  data  indicate  that  each  of the  monoclonal  anti-CRI 
antibodies reacts with  an  idiotypic determinant  that  is part  of or very close to  the 
hapten-binding site of the anti-Ar HP R16.7. 
With rabbit anti-CRI as the labeled ligand, only Ar-HPP was an effective inhibitor 
of binding at the concentrations tested. The weak inhibitory capacity of "the smaller 
haptens  might  be attributable either to  a  higher affinity for idiotype of the  rabbit 
anti-CRI,  as compared  to  the  monoclonal  anti-CRI  antibodies or  to  greater  steric 
interference by the haptens  with  the interactions of the monoclonal  anti-CRI  anti- 
bodies. 
Inhibition  of the Interaction of 126Llabeled Anti-CRI HP with Anti-At Antibody or HP R16. 7 
by  Unlabeled  Anti-CRI HP.  The  data  in Table V  provide further  evidence  that  the 
three monoclonal anti-CRI antibodies combine with the same region of CRI + serum 
anti-Ar antibodies or of CRI + HP R16.7.  The table shows the results of experiments 
in  which  various  unlabeled  anti-CRI  preparations  were  allowed  to  compete  with 
labeled  purified  anti-CRI  antibodies  for  binding  to  immobilized  serum  anti-Ar 
antibody or HP R16.7. 
Two  conclusions may be drawn  from  the data.  First, there is mutual competition 
between  each  pair  of anti-CRI  HP  or  between  each  HP  and  rabbit  anti-CRI  for 
binding either to serum anti-Ar or to HP  R16.7.  Second, HP  2F6.4 appears to bind 
with higher affinity to the idiotypic determinant on CRI + molecules. The possibility 
of higher affinity is supported by the fact that 2F6.4 not only competes more effectively 
than  the  other  anti-CRI  HP  against  labeled 2F6.4  but  also  is  more  effective than 
unlabeled 7B7.10 or 1F2.1  in displacing labeled 7B7.10 or labeled 1F2.1, respectively. 
Similarly, the rabbit anti-CRI might bind with a higher affinity than 7B7.10 or 1F2.1, 
as shown by its superior capacity to displace 2F6.4 from binding to serum anti-Ar or 
to HP R16.7. 
TABL~  IV 
Inhibition by Haptens of the Binding of Labeled Anti-CRI Preparations to a CRI  + HP 
Hapten 
Labeled anti-CRI tested 
7B7.10  2F6.4  1F2.1  RaCRI 
Hapten concentration required  for 50% inhibition (raM)* 
p-Arsanilate  0.12  2.1  0.13  >25 (31%) 
m-Arsanilate  0.16  3.5  0.48  >25 (19%) 
0-Arsanilate  2.4  >20  2.9  >25  (0%) 
Ar-HPP:~  0.0006  0.004  0.0006  0.6 
p-Aminobenzoate  12  >20  10  >25  (0%) 
Wells of polyvinyl chloride microtiter trays were coated with the CRI  + HP R16.7 at a concentration  of 
29 #g/ml, then incubated for 3 h at room temperature with various concentrations of hapten inhibitors 
before the addition of 10 ng 1251-labeled  anti-CRI HP or l~SI-labeled  specifically purified rabbit anti-CRI 
(RaCRI). 
* Values in parentheses show percent inhibition at 25 mM hapten concentration. 
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TABLE  V 
Competition of Various Anti-CRl Preparations for Binding to CRI + Anti-At Antibody  or to a CRI + HP 
1251.1a. 
Exper-  Coating of  beled 
iment  wells  anti- 
CRI 
Unlabeled inhibitor (anti-CRI or nMIgG) 
7B7.10"  2F6.4"  1F2.1"  Ra'CRI:J:  nMIgG 
ng inhibitor required  for 50% inhibition§ 
Purified  A/J  7B7.10  16(100)  8(96)  19(100)  25(100)  >5,000(14) 
Anti-At an-  2F6.4  1,300  (69)  18(99)  3,300  (56)  100  (99)  >5,000  (0) 
tibody  1F2.1  15(100)  3(94)  18  (99)  10  (98)  >5,000  (0) 
Anti-Ar  7B7.10  35(100)  13(94)  31  (97)  50  (99)  >5,000  (0) 
HP, R16.7  2F6.4  500  (70)  9(99)  2400  (61)  54  (99)  >5,000  (4) 
1F2.1  27  (99)  11(93)  65  (99)  40  (96)  >5,000  (1) 
Wells of polyvinyl chloride microtiter trays were coated with purified A/J anti-Ar antibody (6 ~g/m[) 
(experiment  1)  or  with  the CRI*  HP,  R16.7  (10 #g/rot)  (experiment  2).  Various concentrations of 
unlabeled inhibitor proteins were added followed  by 10 ng labeled anti-CRI HP. 
* Anti-CRI HP. 
~: RaCRI, purified rabbit anti-CRI antibody. 
§ Values in parentheses indicate percent inhibition with 5,000 ng inhibitor. 
TABLE  VI 
Suppression  of the Major Cross-Reactive Idiotype  in Adult A/J Mice by RaCRI or by Anti-Idiotypic HP 
Number  Anti-CRI  Dose  Anti-Ar titer mean  Anti-Ar antibody required for 50% 
of mice  (range)  inhibition* 
rng/ml  ng 
5  None  --  0.53(0.44-1.8)  13, 98, 22, 24, 54 
4  RaCRI  100 #g IBC:~  1.3(0.9-1.5)  1,300, 1,200, 80, 700 
4  7B7.10  300 #g  2.8(2.0-4.4)  1,000, 170, 300,  1,300 
4  100 #g  2.4(1.0-3.1)  160, 260,  130, 230 
5  10 #g  2.2(0.7-3.4)  >2,000,  1,800, >4,000, 80, >4,000 
5  I #g  3.3(1.0-5.2)  840, 780, 490, >4,000, 60 
4  2F6.4  300 #g  1.9(0.9  2.9)  3,200, 4,000, 3,000, 2,100 
4  100 g,g  1.7(0.9-4.5)  4,000, 2,000, 3~800, 700 
6  10/~g  4.0(2.2-7.9)  4,000,  150, 400, 58, 42, 75 
6  1 #g  3.0(0.18-8.9)  180, >4,000, 70, 600, >4,000, 50 
3  1F2.1  100/~g  1.5(1.0  2.2)  400,  100, 100 
5  10#g  2.6(1.0  3.9)  63, 29, 31, 23, 28 
6  1/Lg  3.7(1.9  4.6)  89, 23, 92, 76, 39, 500 
Adult A/J were inoculated with various anti-CRI preparations i.p.  on days -3 and 0,  immunized on 
days 14 and 28 with 125/~g KLH-Ar emulsified in complete Freund's adjuvant, and bled on day 40. 
* Each test utilized  10 ng labeled A/J anti-Ar antibody and slightly less than an equivalent amount of 
rabbit anti-CRI. Immune complexes were precipitated with goat anti-rabbit Fc. 
IBC, idiotype-binding capacity as determined by radioimmune assay.  The values for the anti-CRI HP 
are weights of protein injected. 
Suppression  of CRI Formation  by Monoclonal  Anti-CRI.  The  results in Table  VI  show 
that two of the three anti-CRI  HP,  2F6.4 and  7B7.10, are capable of suppressing CRI 
formation  when  inoculated  into  adult  mice  (8-14  wk  of age)  before  immunization 
with  KLH-Ar.  (The  protocol  is  given  in  a  footnote  to  Table  VI).  Suppression  of 
idiotype was observed in a  significant percentage  of the mice when  as little as  1 #g of 
anti-CRI  HP  was  inoculated;  smaller doses were  not  tested. There  was no reduction 1760  MONOCLONAL  ANTI-IDIOTYPIC ANTIBODIES 
of total anti-Ar titers associated with the inoculation of the anti-CRI antibodies. The 
reason for the ineffectiveness of HP  1F2.1  in suppressing the CRI is not known. 
Discussion 
The present  experiments  further define a  family of molecules that  constitute the 
major cross-reactive idiotype associated with A/J anti-Ar antibodies. Serological and 
amino  acid  sequence  analysis  have  shown  (8-13)  that  molecules  expressing  the 
idiotype exhibit  microheterogeneity. Amino acid sequence variations occur both  in 
framework  and  hypervariable  regions;  however,  there  appears  to  be  at  least  90% 
homology of sequence between the H  or L chains of any pair of CRI  + HP studied so 
far. At the serological level, microheterogeneity is shown by the variation in inhibitory 
capacities of CRI  + HP  in  the  radioimmune assay for CRI and  by the  presence  of 
"private" idiotypic determinants on individual CRI  + HP that are not detectable on 
other CRI  ÷ HP (t2, 25). (Such private determinants are, however, generally detectable 
at low levels  in pooled A/J anti-Ar serum). 
The  present  data  demonstrate  that  8  of 10  CRI  +  HP  tested  express  a  common 
idiotypic  determinant  reactive  with  each  of three  monoclonal  anti-idiotypic  anti- 
bodies;  these CRI  + HP vary greatly in their quantitative  inhibitory capacity in  the 
radioimmune assay for CRI when  heterologous anti-CRI antibodies  are  used  (12). 
The presence of a common or shared idiotypic determinant was shown in the present 
study  by  inhibition  tests  in  which  the  anti-Ar  HP  were  allowed  to  compete with 
labeled  purified A/J anti-Ar antibodies or with  a  labeled  CRI  + HP for binding to 
monoclonal anti-CRI.  8  of 10 of the  anti-Ar HP proved  to be strong inhibitors  of 
binding,  and  the  quantitative  variation  (weight  required  for  50%  inhibition)  was 
relatively small. When high concentrations of anti-Ar HP were used, the displacement 
of the  labeled  serum  antibody or CRI  +  HP was  virtually complete.  The  fact  that 
monoclonal anti-Ar HP were about equivalent to unlabeled serum anti-Ar in inhibi- 
tory  capacity  is  particularly  informative  because  it  suggests  conservation  of  the 
determinant in the bulk of the serum idiotype population and supports the conclusion 
that the anti-Ar HP are representative of serum antibodies. It should be noted that 
the  three  monoclonal anti-CRI antibodies were derived from different  clones.  Evi- 
dence for this was the variation in electrophoretic mobility despite  the fact that all 
three  were  IgGv Also, one of the  monoclonal anti-CRI antibodies  has  a  distinctly 
higher affinity for CRI than the other two. 
There app,~ars  to be some microheterogeneity, even with respect  to the relatively 
conserved determinant. One of ten CRI  + HP was a poor inhibitor of binding of each 
of the three monoclonal HP and another inhibited poorly in two of the three systems. 
Evidence for microheterogeneity in the serum antibody population was the fact that 
the monoclonal anti-CRI antibodies bound a smaller proportion of the labeled serum 
anti-Ar than was bound by rabbit  anti-CRI directed against a  CRI  + HP. The most 
effective monoclonal anti-CRI, 2F6.4, bound 60% of the CRI  + population defined by 
the rabbit  antiserum.  It was shown that the anti-Ar bound by the monoclonal anti- 
CRI is a  subpopulation of those molecules that  are bound by the rabbit  anti-CRI; 
immobilized rabbit anti-CRI removed all of the labeled anti-Ar reactive with 2F6.4. 
The  idiotope  reactive  with  each  of  the  three  monoclonal  anti-CRI  antibodies 
appears to involve the combining region of anti-Ar antibody. Derivatives of arsanilate 
inhibited  the  interaction  of each anti-CRI HP with  the CRI  + HP,  R16.7, and  the M. J.  NELLES, L.  A. GILL-PAZARIS, AND A.  NISONOFF  1761 
order of inhibitory capacities for different  haptens corresponded with  the expected 
affinities for anti-Ar antibody. Thus, the para-amino  derivative was a  more effective 
inhibitor than the ortho or meta-amino derivative of benzenearsonate, and a compound 
comprising two rings linked by an azo group (as in the immunogen) was much more 
effective than the single-ring molecules. 
Further,  although  less  definitive,  evidence  that  the  three  monoclonal  anti-CRI 
antibodies combined with the same region of A/J anti-Ar antibody was derived from 
competition  experiments,  which  showed  that  the  three  monoclonal  anti-CRI  anti- 
bodies compete for the same antigenic region of A/J serum anti-Ar or of a CRI  + HP. 
One  of the  anti-CRI  HP  as  well  as  rabbit  anti-CRI  combined  with  the  idiotypic 
region with considerably greater affinity than the other two anti-CRI HP. 
Two of the  three  anti-CRI  HP  described  in  this  report  are  able  to  prevent  the 
production of CRI  + anti-Ar antibody in A/J mice when administered before antigen; 
no marked effect on the total synthesis of anti-Ar antibody was noted. The inability 
of one of the anti-CRI HP to suppress formation of CRI  + molecules is not understood. 
It does not seem to be related to antibody class, as all three anti-CRI HP are IgG1K. 
Other  factors involved might be affinity, dose of anti-CRI, time of administration, 
etc.  Nevertheless,  because  the  anti-CRI  HP  are  of murine  origin,  their  ability  to 
suppress  the production  of the CRI  is consistent  with  a  regulatory role for sponta- 
neously  formed anti-CRI  antibodies  (26-30).  In  addition,  recent  studies  (31)  have 
indicated  that  an  anti-CRI  HP  can  substitute  for  antigen  priming  in  vivo in  the 
induction  of delayed-type hypersensitivity or cell-mediated lympholysis against  the 
Ar-hapten  (M.  I.  Greene,  personal  communication).  Thus,  an  anti-CRI  HP  can 
modulate responses at the T  cell level. 
The large degree of suppression of CRI caused by administration of the anti-CRI 
HP  is  also of interest.  The  fact  that  the CRI  was reduced  to  almost  undetectable 
levels in  some suppressed  mice is consistent  with  the presence of a  shared  idiotype 
within the CRI  ÷ family of molecules. 
Summary 
Previous reports have shown that A/J anti-p-azophenylarsonate (anti-At) antibodies 
that share a  major cross-reactive idiotype (CRI) comprise a  family of closely related 
but nonidentical  molecules. Serological studies with CRI  + monoclonal anti-Ar anti- 
bodies have suggested the presence of a  conserved idiotypic determinant  within  the 
family.  The  present  study  utilized  monoclonal  anti-idiotypic  antibodies  to  define 
further the nature of the conserved idiotypic determinant.  It was found that 8 of 10 
CRI  + monoclonal antibodies possess an idiotypic determinant  reactive with each of 
three monoclonal anti-idiotypic antibodies. In addition, ~60% ofCRI  + serum anti-Ar 
antibodies  reacted  with  one  of  the  monoclonal  anti-idiotypic  preparations.  The 
monoclonal  anti-idiotypic  antibodies  react  with  an  idiotope  in  the  region  of the 
hapten-binding  site,  as indicated  by the  ability of free haptens to inhibit  idiotype- 
anti-idiotype interactions.  Finally, two of three monoclonal anti-idiotypic antibodies 
suppressed  the  subsequent  production  of  CRI  +  serum  anti-Ar  antibodies  when 
administered before antigen, without significantly affecting the total anti-Ar response. 
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